Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
878
datasets available to search
ShareScore release 0.9.0
Dataset results
878 results for “human factors”
Data for: The impact of wildlife and environmental factors on hantavirus infection in host and its translation into human risk
<p><span>Identifying factors that drive infection dynamics in reservoir host populations is essential in understanding human risk from wildlife-originated zoonoses. We studied zoonotic <em>Puumala</em> <em>orthohantavirus</em> (PUUV) in the host, the bank vole (<em>Myodes</em> <em>glareolus</em>), populations in relation to the host population, rodent and predator community and environment-related factors and whether these processes are translated into human infection incidence. We used 5-year rodent trapping and bank vole PUUV serology data collected from 30 sites located in 24 municipalities in Finland. We found that PUUV seroprevalence was negatively associated with the abundance of red foxes, but this process did not translate into human disease incidence, which showed no association with PUUV seroprevalence. The abundance of weasels, the proportion of juvenile bank voles in the host populations and rodent species diversity were negatively associated with the abundance index of PUUV-positive bank voles, which, in turn, showed a positive association with human disease incidence. Our results suggest certain predators, high proportion of young bank vole individuals and a diverse rodent community, may reduce PUUV risk for humans through their negative impacts on the abundance of infected bank voles.</span></p>
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Local
ClinicalTrials.gov study NCT02924883. IPD Sharing: Not stated. Countries: 9. Publications: 1.
Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer
ClinicalTrials.gov study NCT03451162. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
ClinicalTrials.gov study NCT03154086. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
ClinicalTrials.gov study NCT02163577. IPD Sharing: Not stated. Countries: 4. Publications: 3.
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
ClinicalTrials.gov study NCT01441596. IPD Sharing: Not stated. Countries: 8. Publications: 1.
A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
ClinicalTrials.gov study NCT02748213. IPD Sharing: Not stated. Countries: 15. Publications: 1.
A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
ClinicalTrials.gov study NCT01268150. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Pos
ClinicalTrials.gov study NCT02896855. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
ClinicalTrials.gov study NCT01572038. IPD Sharing: Not stated. Countries: 39. Publications: 1.
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive
ClinicalTrials.gov study NCT01491737. IPD Sharing: Not stated. Countries: 8. Publications: 1.
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast
ClinicalTrials.gov study NCT01566721. IPD Sharing: YES. Countries: 59. Publications: 2.
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
ClinicalTrials.gov study NCT01684878. IPD Sharing: Not stated. Countries: 10. Publications: 1.
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
ClinicalTrials.gov study NCT01702571. IPD Sharing: Not stated. Countries: 43. Publications: 3.
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
ClinicalTrials.gov study NCT04288089. IPD Sharing: YES. Countries: 2. Publications: 1.
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
ClinicalTrials.gov study NCT00233519. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer
ClinicalTrials.gov study NCT01432886. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
ClinicalTrials.gov study NCT01401166. IPD Sharing: Not stated. Countries: 12. Publications: 5.
A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females
ClinicalTrials.gov study NCT00800436. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positiv
ClinicalTrials.gov study NCT02132949. IPD Sharing: Not stated. Countries: 12. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.